NCT02146157已完成不适用
A Randomized, Double-blind, Placebo-controlled Trial to Assess Efficacy and Tolerability of an Herb and Mineral Combination Product on Fasting Glucose in Adults at Risk for Developing Diabetes
NewChapter, Inc.11 个研究点 分布在 1 个国家目标入组 104 人开始时间: 2013年2月1日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 104
- 试验地点
- 11
- 主要终点
- Change from Baseline in fasting blood glucose
研究概览
简要总结
This is a multi-center, randomized, double-blind, placebo-controlled study in approximately 104 subjects (52 per group) to evaluate the effectiveness of an herb and mineral combination product on fasting serum glucose levels in subjects with impaired fasting glucose. The study consists of 5 visits: a Screening visit, followed by a Baseline visit (at which eligible subjects will be randomized to product to consume throughout the 12-week supplementation period), followed by Supplementation period visits at 3, 6 and 12 weeks after baseline.
详细描述
The target population of this clinical trial is otherwise healthy, pre-diabetic adults who present with impaired fasting glucose.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Basic Science
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Be male or female, at least 18 years of age
- •If age ≥45 years, must have a body mass index ≥ 25 kg/m2
- •If age <45 years, must have a body mass index ≥ 25 kg/m2 AND present with at least one additional risk factors for developing diabetes.
- •Agree to use contraception throughout study period, unless postmenopausal or surgically sterile (women only)
- •Be able to understand the nature and purpose of the study including potential risks and side effects
- •Be willing to consent to study participation and to comply with study requirements
- •Have a finger stick fasting blood glucose between 105 and 140 mg/dL and a serum fasting glucose between 100 and 125 mg/dL, measured at screening
排除标准
- •Have diabetes (type I or II) or an HBA1c measurement >6.5% at any time in the past or at the screening visit
- •Have been taking within 2 weeks of screening any dietary supplement including vitamin and mineral complexes; herbal supplements; fish oil; fiber supplements; or any herbal ingredient/product that significantly affects glucose metabolism
- •Have been taking within 4 weeks of screening any prescription or over-the-counter (OTC) medication that significantly affects glucose metabolism, including but not limited to, sulfonylureas, meglitinides, biguanides, thiazolidinediones, alpha-glucosidase inhibitors, Inhibitors of dipeptidyl peptidase 4 (DPP-4 inhibitors), systemic corticosteroids
- •Daily use of non-steroidal anti-inflammatory drugs (NSAIDS) (daily baby aspirin use and continuous use of NSAIDS for 3 days or less for acute aches and pains are acceptable)
- •Any co-morbidity or treatment that could, in the opinion of the investigator, preclude the subject's ability to successfully and safely complete the study or that may confound study outcomes
- •Anticipated changes in dietary patterns or physical activity levels during the study, including attempts at body weight reduction
- •Eating disorder
- •Polycystic ovary syndrome
- •Known allergies or intolerance to any substance in the study product
- •Are pregnant or breastfeeding women
- •History of alcohol, drug, or medication abuse
- •Have participated in another study with any investigational product within 1 month of screening
- •Had a recent (<3 months) gastrointestinal surgery or any planned surgery during the clinical study
结局指标
主要结局
Change from Baseline in fasting blood glucose
时间窗: Day 84
Fasting glucose will be measured on serum samples obtained at screening (to be used as baseline value) and at day 84
次要结局
- Change from Baseline in fasting serum glucose(Day 42)
- Change from Baseline in fasting blood glucose(Day 21)
- Change from Baseline in HbA1c(Day 84)
- Change from Baseline in fasting lipids(Day 21)
- Change from Baseline in BMI(Day 84)
- Change from Baseline in waist-to-hip ratio(Day 84)
研究者
研究点 (11)
Loading locations...
相似试验
Unknown
2 期
Vortioxetine for Treatment of Depressive Mood and Alcohol UseDepressive Disorder, MajorAlcoholismNCT04498897Hanyang University Seoul Hospital128
Unknown
2 期
Study to Evaluate Effects of INL1 in Patients With Heart Failure and Reduced Ejection FractionReduced Ejection FractionHeart FailureNCT03875183Innolife Co., Ltd.200
已完成
2 期
Evaluate the Efficacy and Safety of D-2570 in Participants With Moderate-to-Severe Plaque PsoriasisPlaque PsoriasisNCT06278350InventisBio Co., Ltd161
Unknown
3 期
Study of Tyroserleutide for Injection in Hepatocellular Carcinoma (HCC) PatientsHepatocellular,CarcinomaNCT01489566Shenzhen Kangzhe Pharmaceutical Co., Ltd.300
已完成
1 期
Safety Study of AMG 557 in Subjects With Lupus ArthritisLupus Arthritis, Systemic Lupus ErythematosusNCT01683695Amgen20